1. Home
  2. PRSO vs INTS Comparison

PRSO vs INTS Comparison

Compare PRSO & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

N/A

Current Price

$0.64

Market Cap

13.4M

Sector

Technology

ML Signal

N/A

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.53

Market Cap

11.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
INTS
Founded
2008
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
11.4M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
PRSO
INTS
Price
$0.64
$4.53
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$3.00
$38.00
AVG Volume (30 Days)
270.3K
31.7K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
81.23
N/A
EPS
N/A
N/A
Revenue
$14,573,000.00
N/A
Revenue This Year
$18.48
N/A
Revenue Next Year
$53.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.99
N/A
52 Week Low
$0.58
$0.22
52 Week High
$2.37
$8.06

Technical Indicators

Market Signals
Indicator
PRSO
INTS
Relative Strength Index (RSI) 39.26 66.29
Support Level $0.60 $4.50
Resistance Level $0.92 $5.00
Average True Range (ATR) 0.04 0.31
MACD 0.00 0.10
Stochastic Oscillator 21.58 85.03

Price Performance

Historical Comparison
PRSO
INTS

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: